These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11858871)

  • 21. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Licensing procedures for human vaccines in Germany and Europe and the WHO prequalification program].
    Grabski E; Hildt E; Wagner R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Jan; 63(1):4-15. PubMed ID: 31776598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory pathways for vaccines for developing countries.
    Milstien J; Belgharbi L
    Bull World Health Organ; 2004 Feb; 82(2):128-33. PubMed ID: 15042235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Licensure, Approval, and Uptake of Vaccines in the United States.
    Pickering LK; Orenstein WA
    J Pediatric Infect Dis Soc; 2018 Dec; 7(suppl_2):S46-S48. PubMed ID: 30590618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancing public confidence in vaccines through independent oversight of postlicensure vaccine safety.
    Salmon DA; Moulton LH; Halsey NA
    Am J Public Health; 2004 Jun; 94(6):947-50. PubMed ID: 15249296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The complexity and cost of vaccine manufacturing - An overview.
    Plotkin S; Robinson JM; Cunningham G; Iqbal R; Larsen S
    Vaccine; 2017 Jul; 35(33):4064-4071. PubMed ID: 28647170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preventive medicines: vaccination, prophylaxis of infectious diseases, disinfectants.
    Heininger U
    Handb Exp Pharmacol; 2011; 205():317-37. PubMed ID: 21882119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New challenges in assuring vaccine quality.
    Dellepiane N; Griffiths E; Milstien JB
    Bull World Health Organ; 2000; 78(2):155-62. PubMed ID: 10743279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Informing vaccine decision-making: A strategic multi-attribute ranking tool for vaccines-SMART Vaccines 2.0.
    Knobler S; Bok K; Gellin B
    Vaccine; 2017 Jan; 35 Suppl 1():A43-A45. PubMed ID: 28017435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in conducting post-authorisation safety studies (PASS): A vaccine manufacturer's view.
    Cohet C; Rosillon D; Willame C; Haguinet F; Marenne MN; Fontaine S; Buyse H; Bauchau V; Baril L
    Vaccine; 2017 May; 35(23):3041-3049. PubMed ID: 28465097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety assessment of adjuvanted vaccines: Methodological considerations.
    Tavares Da Silva F; Di Pasquale A; Yarzabal JP; Garçon N
    Hum Vaccin Immunother; 2015; 11(7):1814-24. PubMed ID: 26029975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges in the development, licensure, and use of combination vaccines.
    Postema AS; Myers MG; Breiman RF
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S261-6. PubMed ID: 11709757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost of quality assurance/quality control.
    Johnson DW
    Dev Biol Stand; 1992; 79():193-200. PubMed ID: 1286758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond efficacy: The full public health impact of vaccines.
    Saadatian-Elahi M; Horstick O; Breiman RF; Gessner BD; Gubler DJ; Louis J; Parashar UD; Tapia R; Picot V; Zinsou JA; Nelson CB
    Vaccine; 2016 Feb; 34(9):1139-47. PubMed ID: 26808648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Preparation of vaccines].
    Ruitenberg EJ
    Tijdschr Diergeneeskd; 1990 Apr; 115(8):362-70. PubMed ID: 2186504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pitfalls of field trials in fish vaccinology.
    Mitchell H
    Dev Biol Stand; 1997; 90():321-32. PubMed ID: 9270860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory constraints as seen from the pharmaceutical industry.
    Galligani G; David-Andersen I; Fossum B
    Dev Biol (Basel); 2005; 121():235-41. PubMed ID: 15962486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status and future trends in vaccine regulation--USA.
    Falk LA; Ball LK
    Vaccine; 2001 Feb; 19(13-14):1567-72. PubMed ID: 11166876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chinese vaccine products go global: vaccine development and quality control.
    Xu M; Liang Z; Xu Y; Wang J
    Expert Rev Vaccines; 2015 May; 14(5):763-73. PubMed ID: 25697690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine licensure: a proposal to meet changing needs.
    Robbins FC; Mortimer EA
    Ann N Y Acad Sci; 1995 May; 754():368-76. PubMed ID: 7625676
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.